Break B5
- Gender
- Women and men
- Age
- 18 years and older
- Trial type
- Interventional
- Line of therapy
- First line
- Phase
- Phase II
What is this trial about?
The BREAK-B5 trial is investigating the sequence of an intensified immunotherapy regimen.
Detailed description
Immunotherapy has significantly improved the treatment of patients with non-small cell lung cancer in recent years. However, patients with brain metastases generally still do not have a long life expectancy. This study investigates whether intensified immunotherapy, in combination with an antibody (bevacizumab) and chemotherapy at the start of treatment, is well tolerated and can improve patients’ prognosis.
Trial sites
4 trial sites in Germany are listed.
Universitätsklinikum Gießen und Marburg Standort Gießen
Gießen
ClosedUniversitätsklinikum Regensburg
Franz-Josef-Strauss-Allee 11, 93053 Regensburg
Active, not recruitingLMU Klinikum
Active, not recruitingUniversitätsklinikum Augsburg
Active, not recruiting
This list is compiled to the best of our knowledge but without guarantee: it may be incomplete, and a site's recruitment status can change at any time.
- Dr. med. Sebastian SommerSpecialist in internal medicine with a focus on hematology and oncology
- PD Dr. med. Matthias FröhlichSpecialist in internal medicine, immunology and emergency medicine
This description was translated into plain language by our medical editorial team. Whether participation is an option for you is a decision you make together with your treating physician.